Integra LifeSciences (NASDAQ:IART) Updates FY 2024 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) issued an update on its FY 2024 earnings guidance on Monday morning. The company provided earnings per share guidance of 2.410-2.490 for the period, compared to the consensus earnings per share estimate of 2.450. The company issued revenue guidance of $1.6 billion-$1.6 billion, compared to the consensus revenue estimate of $1.6 billion. Integra LifeSciences also updated its Q4 guidance to $0.81-0.89 EPS.

Wall Street Analyst Weigh In

Several analysts recently commented on IART shares. Morgan Stanley raised their price objective on shares of Integra LifeSciences from $24.00 to $27.00 and gave the company an “underweight” rating in a research note on Monday, July 15th. Bank of America reduced their price target on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a research report on Monday, October 7th. Citigroup lowered their price target on Integra LifeSciences from $20.00 to $16.00 and set a “sell” rating on the stock in a report on Tuesday, October 1st. BTIG Research upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating in a research report on Monday, October 7th. Finally, JMP Securities dropped their price target on Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a research report on Tuesday, July 30th. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $26.50.

Integra LifeSciences Price Performance

Shares of NASDAQ:IART opened at $24.53 on Tuesday. Integra LifeSciences has a one year low of $16.81 and a one year high of $45.42. The stock has a market cap of $1.90 billion, a PE ratio of 83.17, a price-to-earnings-growth ratio of 0.66 and a beta of 1.08. The business’s fifty day moving average price is $18.62 and its two-hundred day moving average price is $24.46. The company has a debt-to-equity ratio of 1.17, a quick ratio of 2.10 and a current ratio of 3.39.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Monday, November 4th. The life sciences company reported $0.41 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.02. Integra LifeSciences had a return on equity of 14.07% and a net margin of 1.51%. The business had revenue of $380.80 million for the quarter, compared to analyst estimates of $375.81 million. During the same quarter last year, the company earned $0.76 earnings per share. The business’s revenue for the quarter was down .4% compared to the same quarter last year. On average, analysts forecast that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.